Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 408

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 408
---
 average number of common shares outstanding during the period.
Diluted earnings per common share is computed by dividing our net income (loss) available to common stockholders by the sum of the weighted
average number of common shares outstanding during the period, plus the potential dilutive effects of unvested RSUs and shares of common
stock expected to be issued under our Convertible Notes and Series A and B Preferred during the period.

The potential dilutive effect of unvested RSUs outstanding
during the period are calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. The
potential dilutive effect of our Convertible Notes and Series B Preferred Stock outstanding during the period is calculated using the
if-converted method assuming the conversion of Convertible Notes and Series B Preferred as of the earliest period reported or at the date
of issuance, if later, but are excluded if their effect is anti-dilutive.

The following table presents common share equivalents
excluded from the calculation of diluted net income (loss) per share for the years ended December 31, 2024 and 2023, as the effect of
their inclusion would have been anti-dilutive during periods of net loss:

    Schedule of anti dilutive shares 

    Year Ended December 31, 2024  
    Year Ended December 31, 2023 

    Convertible Notes 
     1,125,716  
     1,054,508 
  
    Series B Preferred 
     802,786  
     802,786 
  
    Unvested RSUs 
     510,513  
     541,957 
  
    Total 
     2,439,015  
     2,399,251 

Moreover, in connection with an acquisition of Crossflo
by PTSC (see Note 10), 5,690 escrow shares of common stock were issued that are contingent upon certain representations and warranties
made by Crossflo. We exclude these escrow shares from the basic income (loss) per share calculations and would have included the escrowed
shares in the diluted income per share calculations if we reported net income.

Income Taxes

We follow authoritative guidance in accounting for
uncertainties in income taxes. This authoritative guidance prescribes a recognition threshold and measurement requirement for the financial
statement recognition of a tax position that has been taken or is expected to be taken on a tax return and also provides guidance on dere